PhaseBio Pharmaceuticals downgraded by Stifel with a new price target
$PHAS
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded PhaseBio Pharmaceuticals from Buy to Hold and set a new price target of $1.00 from $15.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2022 | $15.00 → $1.00 | Buy → Hold | Stifel |
| 10/13/2021 | $15.00 | Buy | Stifel |